La cadena de opciones muestra datos clave de las opciones de acciones de Fractyl Health a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Fractyl Health..

Fractyl Health (NASDAQ:GUTS) Bolsa, Cadena de Opciones

Fractyl Health

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.

Mizuho analyst John Roberts maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Neutral and raises the price target from $65 to $67.

News

Price Target

Analyst Ratings

Mizuho Maintains Neutral on LyondellBasell Industries, Raises Price Target to $67

Hongli Group Receives Nasdaq Non-Compliance Notices

Over next two years company creating approximately 700 new jobs across multiple factories and investing up to $100 million in Pennsylvania
<ul>
<li>New jobs at company's Charleroi, PA factory will help manufacture additional high voltage switchgear products essential to operation of the country's electric grids</li>
<li>GE Vernova has now announced plans to create a total of 1,750 new U.S. jobs and to make $680 million in U.S. investments since January</li>
<li>Company also has secured an order to provide seven of its high efficiency natural gas turbines to the Homer City, PA Energy Campus</li>
</ul>
As energy demand continues to surge, GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) plans to add 250 new jobs over the next two years at the company's leading grid solutions factory in Charleroi, PA.
The new roles will help manufacture more high voltage switchgear products, which are critical components for stable and reliable operation of the nation's electrical grids.
GE Vernova now plans to invest up to $100 million in Pennsylvania over the next two years, adding approximately 700 new jobs across multiple factories in the state that will help modernize the grid for economic growth, strengthen domestic supply chains, and boost national security.
This new Charleroi factory expansion builds on the company's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gevernova.com%2Fcompany%2Finvesting-in-manufacturing&amp;esheet=54290548&amp;newsitemid=20250714455569&amp;lan=en-US&amp;anchor=%24600+million+multi-year+investment&amp;index=1&amp;md5=8506edda381daa1de80f33521cea2966">$600 million multi-year investment</a> announced in January, originally expected to create a total of 1,500 new jobs across numerous U.S. factories.

GE Vernova Plans To Add 250 New Jobs Over Next Two Years At Grid Solutions Factory In Charleroi; Secures Order To Provide Seven Of Its Natural Gas Turbines To Homer City Energy Campus

<a href="https://event.webcasts.com/starthere.jsp?ei=1723895&amp;tp_key=4ff3289e48&amp;tp_special=8">https://event.webcasts.com/starthere.jsp?ei=1723895&amp;tp_key=4ff3289e48&amp;tp_special=8</a>

JP Morgan CFO Says All The Tail Risks In The Market Are Still There; Says Sentiment Is Better In Investment Banking But We Remain Cautious Considering All The Risks; Says The Credit Card Landscape Is Very Competitive

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares are rising Tuesday. The company selected a lead constructor for its first Aurora powerhouse. Additionally, Cantor Fitzgerald initiated coverage on Oklo with an <a href="https://www.benzinga.com/pressreleases/25/07/b46412257/oklo-selects-kiewit-as-the-lead-constructor-for-first-aurora-powerhouse-in-idaho">Overweight rating.</a>
What To Know: Oklo on Tuesday announced a newly executed Master Services Agreement in which it chose Kiewit Nuclear Solutions as the lead constructor for its first commercial Aurora powerhouse in Idaho.
Under the agreement, Kiewit will&nbsp;support the design, procurement and construction of the powerhouse, with pre-construction expected to begin in 2025. 
&#8220;We&#8217;ve completed key pre-construction milestones, including site characterization work in Idaho, in partnership with the U.S. Department of Energy and Idaho National Laboratory,&#8221; said Jacob DeWitte, co-founder and CEO of Oklo. 
&#8220;Kiewit brings the execution strength and project delivery experience that are essential as we move into this next phase.&#8221;
A significant portion of the Aurora powerhouse&#8217;s construction scope is non-nuclear. Through its agreement with Kiewit, Oklo believes it can accelerate delivery timelines and reduce overall costs.
Oklo is targeting deployment of its first nuclear powerhouse in late 2027 or early 2028. The company&#8217;s CEO&nbsp;<a href="https://www.benzinga.com/government/regulations/25/05/45625025/oklo-ceo-says-recent-developments-surrounding-nuclear-could-move-company-timelines-forward" target="_blank" rel="noreferrer noopener">said</a>&nbsp;in May that timelines could potentially be accelerated after President&nbsp;Donald Trump&nbsp;signed multiple executive orders aimed at supporting the&nbsp;domestic nuclear industry.
Oklo shares also appear to be getting a boost on Tuesday after Cantor Fitzgerald analyst Derek Soderberg initiated coverage with an Overweight rating and set a price target of $73, flagging the company as a potential leader in the coming multi-trillion-dollar grid expansion.
Soderberg said Oklo is positioned to be able to deploy efficient, cost-effective energy for the AI economy, with small modular reactors that are the ideal size for the data center market. 
&#8220;Oklo technology is based on a 30-year operational history and proven fast fission reactor technology, reducing the technology risk. Moreover, Oklo reactors are highly scalable as the vast majority of components have established supply chains,&#8221; the Cantor Fitzgerald analyst wrote in a note. 
The analyst sees a path for Oklo to achieve long-term free cash flow margin of more than 50%. Soderberg also noted that the company&#8217;s fuel recycling technology provides upside potential to its profitability. 
&#8220;We believe Oklo will be a big winner,&#8221; the analyst said.
OKLO Price Action: <a href="http://benzinga.com/quote/OKLO" target="_blank" rel="noreferrer noopener">Oklo shares</a> are up approximately 193% year-to-date. The stock was up 1.27% at $63.20 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/small-cap-analysis/25/07/46299343/oklo-nuscale-hims-defy-trump-tariffs-and-power-the-russell-2000-toward-new-highs">Oklo, NuScale, Hims Defy Trump Tariffs &#8211; And Power The Russell 2000 Toward New Highs</a></li>
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46413961/june-inflation-cpi-report">June Inflation Lands As Expected — But Cooler Core Reading Fuels Fed Rate Cut Hopes</a></li>
</ul>
Photo: courtesy of Oklo.

Initiation

Movers

OKLO

Oklo Stock Is Rising Tuesday: What's Going On?

Mizuho analyst John Roberts maintains Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Outperform and lowers the price target from $39 to $35.

AXTA

Mizuho Maintains Outperform on Axalta Coating Systems, Lowers Price Target to $35

<ul>
<li>NVDA</li>
<li>AMD</li>
<li>CORN</li>
<li>GLD</li>
<li>TSLA</li>
<li>$BTC</li>
<li>GOOGL</li>
<li>BULL</li>
<li>HOOD</li>
<li>BABA</li>
</ul>
Data From <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

$BTC

BABA

BULL

CORN

GOOGL

HOOD

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 15, 2025 (Via Swaggy Stocks)

Mizuho analyst John Roberts maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Outperform and raises the price target from $125 to $135.

Mizuho Maintains Outperform on PPG Indus, Raises Price Target to $135

As of July 15, 2025, two stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Trade Desk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>)</h3>
<ul class="wp-block-list">
<li>On July 14, the S&amp;P Dow Jones Indices revealed that Trade Desk would replace ANSYS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANSS#NASDAQ">ANSS</a>) in the S&amp;P 500, effective from the market open on July 18. The company's stock jumped around 7% over the past month and has a 52-week high of $141.53.</li>
<li>RSI Value: 75.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TTD Price Action: Shares of Trade Desk rose 0.1% to close at $75.43 on Monday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/ttd"><img loading="lazy" decoding="async" width="406" height="170" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15074918/image-170.png" alt="" class="wp-image-985769" style="width:267px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15074918/image-170.png 406w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15074918/image-170-300x126.png 300w" sizes="(max-width: 406px) 100vw, 406px" /></a></figure>
<h3 class="wp-block-heading">So-Young International Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>)</h3>
<ul class="wp-block-list">
<li>On July 3, So-Young International regained Nasdaq compliance for its closing bid price. The company's stock gained around 346% over the past month and <a href="https://www.benzinga.com/quote/SY">has a 52-week high</a> of $4.84.</li>
<li>RSI Value: 81</li>
<li>SY Price Action: Shares of So-Young International gained 10.4% to close at $4.24 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>.
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

ANSS

Top 2 Tech & Telecom Stocks That May Keep You Up At Night This Month

Q.E.P. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/QEPC#OTC">QEPC</a>) reported quarterly earnings of $1.36 per share. This is a 16.24 percent increase over earnings of $1.17 per share from the same period last year. The company reported $61.528 million in sales this quarter. This is a 3.14 percent decrease over sales of $63.524 million the same period last year.

Earnings

QEPC

Q.E.P. Q1 EPS $1.36 Up From $1.17 YoY, Sales $61.528M Down From $63.524M YoY

Company Plans to Report Second Quarter 2025 Results on August 12, 2025
MORTON GROVE, Ill., July 15, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) ("Lifeway" or "the Company"), a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, today announced a milestone achievement of surpassing $5.5 million in gross sales for the week ending July 13th, 2025, representing a 66% increase from the prior year.

LWAY

Lifeway Foods Reports 66% Growth In Weekly Gross Sales, Surpassing $5.5M

<a href="https://event.webcasts.com/starthere.jsp?ei=1723895&amp;tp_key=4ff3289e48&amp;tp_special=8" title="https://event.webcasts.com/starthere.jsp?ei=1723895&amp;tp_key=4ff3289e48&amp;tp_special=8">https://event.webcasts.com/starthere.jsp?ei=1723895&amp;tp_key=4ff3289e48&amp;tp_special=8</a>

Guidance

JPMorgan CFO Barnum During Q2 Earnings Conf. Call Says Struggle To See Signs Of Weakness In Consumer Segment; Tail Risks In Market Still; CEO Dimon Says Credit Spreads Low In Private Credit But Has Grown "Dramatically" Over Time

<a href="https://www.gov.uk/cma-cases/schlumberger-slash-championx-merger-inquiry" title="https://www.gov.uk/cma-cases/schlumberger-slash-championx-merger-inquiry">https://www.gov.uk/cma-cases/schlumberger-slash-championx-merger-inquiry</a>

Legal

UK's CMA Says It Has Accepted Undertakings In Lieu: Schlumberger/ChampionX Deal; Says Anticipated Acquisition By SLB Of ChampionX Will Not Be Referred To Phase 2 Probe; Says Anticipated Acquisition By SLB Of ChampionX Will Not Be Referred To An In-Depth, Phase 2 Investigation

Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) reported better-than-expected second-<a href="https://www.benzinga.com/quote/FAST/earnings">quarter earnings</a> on Monday.
Fastenal reported quarterly earnings of 29 cents per share which beat the analyst consensus estimate of 28 cents per share. The company reported quarterly sales of $2.08 billion which beat the analyst consensus estimate of $2.07 billion.
Gross margin rose slightly to 45.3% of net sales, driven by modest price/cost benefits and improved fastener margins tied to product expansion and supplier programs. Operating income increased to 21% of sales, up from 20.2% in the second quarter of 2024.
For 2025, net capital outlays are expected to range from $250 million to $270 million, below earlier guidance but above 2024 levels. The increase reflects distribution center upgrades, delayed IT initiatives, and hardware deployments.
Fastenal shares gained 4.2% to close at $45.07 on Monday.
These analysts made changes to their price targets on Fastenal following earnings announcement.
<ul class="wp-block-list">
<li>Stephens &amp; Co. analyst Tommy Moll maintained Fastenal with an Equal-Weight rating and raised the price target from $40 to $45.</li>
<li>Baird analyst David Manthey maintained the stock with a Neutral and raised the price target from $43 to $47.</li>
</ul>
Considering buying FAST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/FAST/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15092138/image-180-1024x602.png" alt="" class="wp-image-985987" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15092138/image-180-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15092138/image-180-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15092138/image-180-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15092138/image-180.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

FAST

Fastenal Analysts Boost Their Forecasts After Upbeat Earnings

Earnings Beats

Wells Fargo Q2 Adj. EPS $1.54 Beats $1.40 Estimate

State Street Q2 Adj. EPS $2.53 Beats $2.37 Estimate

Mizuho analyst John Roberts maintains Orion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OEC#NYSE">OEC</a>) with a Neutral and lowers the price target from $12 to $10.

Mizuho Maintains Neutral on Orion, Lowers Price Target to $10

Wells Fargo analyst Roger Read maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Equal-Weight and lowers the price target from $47 to $46.

Wells Fargo Maintains Equal-Weight on Occidental Petroleum, Lowers Price Target to $46

During Conf Call, Citigroup CFO Mark Mason Reportedly Says Expects Softer Activity In Second Half Of 2025 But Recession Risk Has Fallen; On Consumer Spending Says Expects Further Cooling As Tariffs Come Through; Inflation Has Shown Limited Effect From Tariffs; Expects To See Continued Momentum In Net New Assets In Wealth Management

During Conf Call, Citigroup CFO Mark Mason Reportedly Says On Investment Banking Pipeline Says Expects To See Activity Pick Up; Much Of Net Credit Losses In The Quarter Were Tied To Credit Card Portfolios; ACL Build This Quarter Related To Transfer Risk In Russia, Dividends On Behalf Of Clients That Bank Is Unable To Distribute; Other Portion Of ACL Build Is Related To Specific Companies Downgrades Related To Lending Portfolio; In Subsequent Quarters Headcount Will Likely Continue To Trend Down

Press Releases

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

Health Care

General

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

GUTS

Apyx Medical

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies Glb

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

CytoSorbents

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Fractyl Health

Fractyl Health (GUTS) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL